1. [CASE 1 — QUESTION 1]
A 54-year-old man received a deceased-donor kidney transplant for diabetic nephropathy. He is CMV donor-positive/recipient-negative (D+/R-) and is maintained on tacrolimus, mycophenolate, and prednisone. He completed three months of valganciclovir prophylaxis, which ended two weeks ago. He now presents with malaise, low-grade fever, and mild leukopenia. Plasma CMV PCR, undetectable during prophylaxis, is rising on serial testing. He has no diarrhea, dyspnea, or visual complaints. Renal function is at baseline. Which is the most appropriate next step in management?
A) Reassure and repeat the CMV PCR in one month, since prophylaxis was completed
B) Begin empiric foscarnet, presuming post-prophylaxis CMV is ganciclovir-resistant
C) Initiate treatment-dose valganciclovir (or IV ganciclovir) for this episode of late-onset CMV infection and continue serial CMV PCR to confirm a virologic response
D) Permanently discontinue mycophenolate and start letermovir as treatment
E) Obtain colonoscopy and bronchoscopy before starting any antiviral therapy
ANSWER: C
Rationale:
This is the prototypical late-onset CMV picture in a D+/R- recipient after universal prophylaxis is stopped. Option C is correct: a rising viral load with compatible symptoms in a high-risk recipient who has just finished prophylaxis represents late-onset CMV infection, treated with treatment-dose valganciclovir or IV ganciclovir and serial PCR to confirm response, alongside review of immunosuppression.
Option A: Option A is incorrect: a rising load with symptoms warrants treatment, not a one-month delay.
Option B: Option B is incorrect: resistance is not presumed at a first episode; it is suspected only after about two weeks of adequate therapy without a one-log decline, then confirmed by genotyping.
Option D: Option D is incorrect: letermovir is a low-barrier prophylactic agent, not first-line treatment for active replication, and abruptly stopping mycophenolate entirely is not indicated here.
Option E: Option E is incorrect: with no localizing tissue-invasive symptoms, empiric pan-endoscopy is unnecessary and should not delay therapy. Late-onset CMV is the recognized trade-off of the universal prophylaxis strategy.
2. [CASE 1 — QUESTION 2]
Continuing with the same patient. He is started on appropriately dosed valganciclovir. After 16 days of confirmed-adherent therapy his CMV viral load has not declined by even one log10 and his symptoms persist. Renal function and drug dosing have been verified as adequate. What is the most appropriate next step?
A) Send genotypic resistance testing of the UL97 and UL54 genes to identify a resistance mutation and guide the next agent
B) Continue the same valganciclovir for another two weeks before reassessing
C) Add corticosteroids to suppress an inflammatory component of CMV disease
D) Switch to letermovir monotherapy as definitive treatment of active replication
E) Discontinue all antiviral therapy and rely on immune reconstitution alone
ANSWER: A
Rationale:
Failure of the viral load to fall by at least one log10 after roughly two weeks of adequate therapy is the trigger to investigate resistance. Option A is correct: genotypic testing of UL97 (phosphotransferase) and UL54 (DNA polymerase) identifies the resistance mechanism and directs the next agent.
Option B: Option B is incorrect: continuing a failing regimen wastes time and allows progression.
Option C: Option C is incorrect: corticosteroids do not treat CMV replication and deepen immunosuppression.
Option D: Option D is incorrect: letermovir has a low resistance barrier and is inappropriate as treatment for active, high-level replication.
Option E: Option E is incorrect: abandoning therapy in active CMV disease is unsafe; immune reconstitution is an adjunct, not a substitute. Genotype-guided switching is the rational pathway when first-line therapy fails.
3. [CASE 1 — QUESTION 3]
Continuing with the same patient. Genotyping returns an isolated UL97 mutation (codon 594) with a wild-type UL54 gene. His white count has fallen further during valganciclovir, with an ANC of 900/microliter. Which is the most appropriate change in therapy?
A) Increase the valganciclovir dose, since the UL54 polymerase remains susceptible
B) Add maribavir to valganciclovir to enhance ganciclovir activation
C) Continue valganciclovir and add filgrastim, since the resistance is only partial
D) Start cidofovir as the sole option, accepting unavoidable nephrotoxicity
E) Switch to foscarnet, which requires no UL97-mediated activation and is non-myelosuppressive, while monitoring renal function and repleting calcium, magnesium, and potassium
ANSWER: E
Rationale:
This integrates the resistance genotype with the patient's worsening marrow status. Option E is correct: an isolated UL97 mutation impairs ganciclovir activation, but wild-type UL54 leaves the polymerase susceptible to foscarnet, which needs no activation and is non-myelosuppressive — an advantage given his falling counts — with the caveat that nephrotoxicity and electrolyte wasting require monitoring and repletion.
Option A: Option A is incorrect: dose escalation cannot overcome a UL97 activation defect.
Option B: Option B is incorrect: maribavir inhibits UL97 and would further impair ganciclovir activation, making the combination antagonistic.
Option C: Option C is incorrect: the resistance defeats ganciclovir regardless of neutrophil support.
Option D: Option D is incorrect: cidofovir is generally reserved for later lines given its nephrotoxicity when foscarnet is available for UL97 resistance. Foscarnet is the standard switch for isolated UL97-mediated ganciclovir resistance.
4. [CASE 1 — QUESTION 4]
Continuing with the same patient. Two days into foscarnet he develops perioral and fingertip tingling, muscle cramps, and a positive Chvostek sign during an infusion; ECG shows a newly prolonged QTc. What is the most likely cause and the correct response?
A) Tacrolimus neurotoxicity unrelated to foscarnet; no electrolyte evaluation is needed
B) Foscarnet-induced electrolyte disturbance — chelation of divalent cations causing hypocalcemia and hypomagnesemia (often with hypokalemia); measure and replete calcium, magnesium, and potassium, repletion before each subsequent infusion, and reassess the QTc
C) Acute hypercalcemia from foscarnet; treat with saline diuresis and a bisphosphonate
D) A benign infusion reaction requiring no monitoring or intervention
E) Ganciclovir withdrawal effect; resume ganciclovir to stabilize membranes
ANSWER: B
Rationale:
The cluster of perioral/peripheral paresthesias, tetany signs, cramps, and QTc prolongation during foscarnet points to its characteristic electrolyte toxicity. Option B is correct: foscarnet chelates ionized divalent cations, producing hypocalcemia and hypomagnesemia (and often hypokalemia), which cause neuromuscular irritability and QTc prolongation; the response is to measure and replete calcium, magnesium, and potassium, replete before each infusion, and reassess the QTc.
Option A: Option A is incorrect: although tacrolimus can be neurotoxic, the tetany and QTc changes during foscarnet are best explained by its electrolyte wasting, and electrolytes must be checked.
Option C: Option C is incorrect: foscarnet causes hypocalcemia, not hypercalcemia, so this treatment is exactly wrong.
Option D: Option D is incorrect: these are signs of a clinically important, potentially dangerous derangement, not a benign reaction.
Option E: Option E is incorrect: his CMV is UL97-resistant, so resuming ganciclovir is both ineffective and irrelevant to electrolyte correction. Mandatory pre-infusion electrolyte repletion is a defining feature of safe foscarnet use.
5. [CASE 2 — QUESTION 1]
A 41-year-old woman undergoes allogeneic hematopoietic stem cell transplant (HSCT) for acute myeloid leukemia. She is CMV-seropositive (R+), and the conditioning regimen has left her with profound, prolonged neutropenia. The team wants to prevent CMV reactivation without worsening her marrow suppression. Which prophylactic agent is best suited to this situation, and why?
A) Valganciclovir, because its myelosuppression is offset by its oral convenience
B) Acyclovir, because it covers CMV as effectively as it covers HSV
C) Cidofovir, because its weekly dosing minimizes cumulative marrow toxicity
D) Letermovir, because it inhibits the CMV-specific terminase complex (an enzyme with no human counterpart) and therefore has no myelosuppressive effect, an advantage in a neutropenic HSCT recipient
E) Foscarnet, because it is non-myelosuppressive and requires no monitoring
ANSWER: D
Rationale:
Agent choice in a cytopenic HSCT recipient hinges on avoiding additive marrow toxicity. Option D is correct: letermovir inhibits the CMV terminase complex (UL56/UL89/UL51), a CMV-specific packaging enzyme with no mammalian homologue, and has no myelosuppressive activity, making it the preferred CMV prophylaxis from day 0 through day 100 in seropositive HSCT recipients.
Option A: Option A is incorrect: valganciclovir is myelosuppressive, the very problem to be avoided here.
Option B: Option B is incorrect: acyclovir does not provide effective CMV prophylaxis (CMV lacks the thymidine kinase that activates it).
Option C: Option C is incorrect: cidofovir is nephrotoxic, not a standard HSCT CMV prophylactic, and weekly dosing does not make it marrow-safe in this role.
Option E: Option E is incorrect: although foscarnet is non-myelosuppressive, it is nephrotoxic, requires intensive electrolyte monitoring, and is not used as routine CMV prophylaxis. Letermovir's CMV-specific terminase mechanism is exactly what spares the marrow.
6. [CASE 2 — QUESTION 2]
Continuing with the same patient. She is maintained on tacrolimus for graft-versus-host disease prophylaxis, and letermovir prophylaxis is now begun. What should the team anticipate and do regarding the tacrolimus?
A) Letermovir induces tacrolimus metabolism, so the tacrolimus dose must be increased as levels fall
B) Letermovir is a moderate CYP3A4 inhibitor and will raise tacrolimus concentrations; reduce the tacrolimus dose at letermovir initiation and monitor trough levels closely over the first weeks of combined therapy
C) Letermovir and tacrolimus have no metabolic interaction, so no dose change or monitoring is required
D) Letermovir chelates tacrolimus in the gut, so tacrolimus should be switched to the intravenous route
E) The only interaction is additive myelosuppression with tacrolimus, requiring growth-factor support
ANSWER: B
Rationale:
This applies letermovir's CYP3A4 inhibition to the narrow therapeutic index of a calcineurin inhibitor. Option B is correct: letermovir is a moderate inhibitor of CYP3A4 (and CYP2C8) and increases tacrolimus concentrations (by roughly 40-45%); the tacrolimus dose should be reduced at letermovir initiation with close trough monitoring during the first weeks.
Option A: Option A is incorrect: letermovir inhibits rather than induces CYP3A4, so tacrolimus levels rise, not fall.
Option C: Option C is incorrect: there is a clinically significant interaction requiring adjustment and monitoring.
Option D: Option D is incorrect: the interaction is metabolic CYP3A4 inhibition, not gut chelation, and changing route does not address it.
Option E: Option E is incorrect: tacrolimus is not myelosuppressive, and letermovir's defining interaction here is CYP3A4-mediated elevation of calcineurin inhibitor levels. This metabolic interaction is distinct from letermovir's otherwise clean, non-myelosuppressive profile.
7. [CASE 2 — QUESTION 3]
Continuing with the same patient. On day 60, after letermovir was stopped per protocol, she develops progressive dyspnea, nonproductive cough, and hypoxemia. CT shows bilateral interstitial infiltrates. Blood CMV PCR is negative. What is the most appropriate next diagnostic step?
A) Perform bronchoscopy with bronchoalveolar lavage for CMV testing, because blood CMV PCR can be negative in CMV pneumonitis and tissue-level sampling is required for diagnosis
B) Exclude CMV on the basis of the negative blood PCR and treat for bacterial pneumonia only
C) Begin high-dose corticosteroids for presumed idiopathic pneumonia syndrome without further testing
D) Repeat the blood CMV PCR daily and withhold evaluation until it turns positive
E) Start empiric letermovir, since it is the treatment of choice for CMV pneumonitis
ANSWER: A
Rationale:
Recognizing that blood PCR can be falsely negative in tissue-invasive CMV is the crux of this step. Option A is correct: CMV pneumonitis frequently has a negative blood PCR because the virus replicates at the alveolar level without detectable viremia, so bronchoalveolar lavage is required for diagnosis.
Option B: Option B is incorrect: a negative blood PCR does not exclude tissue-invasive CMV, and missing it can be fatal.
Option C: Option C is incorrect: empiric steroids without diagnosis risk worsening unrecognized CMV.
Option D: Option D is incorrect: passively waiting delays diagnosis in a deteriorating patient.
Option E: Option E is incorrect: letermovir is a prophylactic agent, not a treatment for established CMV pneumonitis. CMV pneumonitis is the most lethal CMV manifestation in allogeneic HSCT, which is why prompt BAL-based diagnosis is essential.
8. [CASE 2 — QUESTION 4]
Continuing with the same patient. Bronchoalveolar lavage confirms CMV pneumonitis. Which treatment approach is most appropriate for this manifestation in an allogeneic HSCT recipient?
A) Letermovir monotherapy, since terminase inhibition is sufficient for established disease
B) Foscarnet monotherapy, deliberately avoiding IVIG, which has no role in pulmonary CMV
C) IV ganciclovir plus intravenous immunoglobulin (IVIG), with reduction of immunosuppression where feasible — combination antiviral-plus-antibody therapy outperforms antiviral monotherapy in observational HSCT data for this high-mortality manifestation
D) Oral valacyclovir, since it concentrates well in lung tissue
E) Corticosteroids alone, since CMV pneumonitis is primarily an inflammatory process
ANSWER: C
Rationale:
CMV pneumonitis is the most lethal CMV manifestation in allogeneic HSCT (30-50% mortality), and management is combination therapy plus immunosuppression reduction. Option C is correct: IV ganciclovir supplies direct antiviral activity, IVIG provides CMV-specific neutralizing antibody at the alveolar surface (combination outperforms antiviral monotherapy in observational HSCT data), and reducing immunosuppression where feasible helps restore host antiviral immunity.
Option A: Option A is incorrect: letermovir is prophylactic and not a treatment for established pneumonitis.
Option B: Option B is incorrect: IVIG is a standard adjunct in CMV pneumonitis, so deliberately omitting it discards a beneficial component.
Option D: Option D is incorrect: valacyclovir does not provide effective anti-CMV therapy.
Option E: Option E is incorrect: CMV pneumonitis is a tissue-invasive viral infection requiring antiviral therapy, not steroids alone. The combination reflects the severity and high mortality of this condition.
9. [CASE 3 — QUESTION 1]
A 7-year-old boy receives an intestinal transplant for short-gut syndrome. He is EBV donor-positive/recipient-negative (D+/R-) and is placed on tacrolimus-based immunosuppression with induction anti-thymocyte globulin. Five months later he develops fever and cervical lymphadenopathy, and serial EBV viral loads are rising rapidly. Which feature of this case confers the highest risk of post-transplant lymphoproliferative disorder (PTLD)?
A) His age alone, independent of serostatus or graft type
B) The use of tacrolimus, which is uniquely lymphoproliferative among immunosuppressants
C) The absence of any antiviral prophylaxis, which directly causes PTLD
D) The kidney-sparing nature of intestinal transplant, which reduces immune monitoring
E) The combination of EBV D+/R- serostatus with primary EBV infection after transplant, a large donor lymphoid burden in the intestinal graft, and T-cell-depleting induction, which together maximize PTLD risk
ANSWER: E
Rationale:
PTLD risk is highest where primary EBV infection meets a heavy donor lymphoid load and intense T-cell depletion. Option E is correct: an EBV-seronegative recipient of an EBV-positive graft who acquires primary EBV infection post-transplant — especially a pediatric intestinal recipient, where the donor lymphoid tissue burden is large — combined with T-cell-depleting induction (anti-thymocyte globulin) produces the highest PTLD risk; intestinal and multivisceral transplants carry the greatest incidence.
Option A: Option A is incorrect: age contributes but is not the determinant independent of serostatus and graft type.
Option B: Option B is incorrect: high cumulative immunosuppression and T-cell depletion raise risk, but tacrolimus is not uniquely lymphoproliferative.
Option C: Option C is incorrect: lack of prophylaxis does not directly cause PTLD; antivirals do not treat established PTLD because latent B cells lack viral thymidine kinase.
Option D: Option D is incorrect: intestinal transplants carry MORE, not less, lymphoid tissue and higher PTLD risk. The convergence of these specific factors is what drives the risk.
10. [CASE 3 — QUESTION 2]
Continuing with the same patient. A biopsy confirms early polymorphic EBV-positive PTLD. A trainee proposes high-dose IV ganciclovir to treat the EBV-driven proliferation. Why is this approach mechanistically ineffective for established PTLD?
A) PTLD B cells overexpress an efflux pump that exports ganciclovir before it acts
B) Ganciclovir penetrates lymphoid tissue too poorly to reach therapeutic levels
C) EBV in PTLD has mutated its DNA polymerase to a ganciclovir-resistant form
D) PTLD is driven by latently infected B cells that do not express the viral thymidine kinase required to activate ganciclovir; the drug acts only on lytically replicating virus, so it is never activated in latency-program cells
E) EBV is an RNA virus, so a DNA polymerase inhibitor is irrelevant
ANSWER: D
Rationale:
The latency-versus-lytic distinction explains the failure of nucleoside analogues in PTLD. Option D is correct: ganciclovir (and acyclovir) require phosphorylation by a virally encoded thymidine kinase expressed only during lytic replication; PTLD is sustained by B cells in the latency program, which do not express viral thymidine kinase, so the drug is never activated and cannot act — PTLD is fundamentally immunological, not lytic.
Option A: Option A is incorrect: efflux-pump export is not the mechanism.
Option B: Option B is incorrect: tissue penetration is not the limiting factor.
Option C: Option C is incorrect: polymerase mutation is not why ganciclovir fails here; the failure is upstream at activation.
Option E: Option E is incorrect: EBV is a double-stranded DNA herpesvirus, not an RNA virus. This is why therapy targets the B-cell reservoir and the immune deficit rather than the viral polymerase.
11. [CASE 3 — QUESTION 3]
Continuing with the same patient. Given early polymorphic EBV-positive PTLD, which intervention should be applied first when clinically feasible?
A) Begin R-CHOP chemotherapy immediately for all PTLD
B) Reduce immunosuppression to allow recovery of EBV-specific cytotoxic T-cell surveillance, the first-line intervention in early PTLD
C) Proceed directly to four weekly doses of rituximab before any change in immunosuppression
D) Start IV ganciclovir, since EBV is a herpesvirus
E) Perform splenectomy to debulk the proliferating B cells
ANSWER: B
Rationale:
The management hierarchy begins with restoring immune surveillance. Option B is correct: reduction of immunosuppression is the first intervention in early polymorphic PTLD wherever feasible, allowing reconstitution of EBV-specific cytotoxic T cells, with response rates of roughly 20-40% in early disease.
Option A: Option A is incorrect: R-CHOP is reserved for aggressive monomorphic disease or failure of earlier steps.
Option C: Option C is incorrect: rituximab is added when reduction of immunosuppression is insufficient or disease progresses — it complements, rather than precedes, the foundational step.
Option D: Option D is incorrect: ganciclovir is ineffective for established PTLD because latent B cells lack viral thymidine kinase.
Option E: Option E is incorrect: splenectomy is not part of the standard hierarchy. In this high-risk pediatric recipient the first lever remains reducing immunosuppression, balanced against the risk of graft rejection.
12. [CASE 3 — QUESTION 4]
Continuing with the same patient. Despite reduction of immunosuppression, his disease progresses, and repeat biopsy now shows monomorphic PTLD histologically resembling diffuse large B-cell lymphoma. Which pharmacological approach is most appropriate?
A) Rituximab (anti-CD20) to deplete the EBV-harboring B-cell reservoir, combined with chemotherapy (R-CHOP) for this monomorphic disease resembling diffuse large B-cell lymphoma
B) High-dose IV ganciclovir, now that the disease has become aggressive
C) Letermovir, to target EBV through terminase inhibition
D) Foscarnet plus cidofovir combination antiviral therapy
E) Observation, since monomorphic PTLD often regresses spontaneously
ANSWER: A
Rationale:
Progression to monomorphic disease escalates therapy to B-cell depletion plus chemotherapy. Option A is correct: rituximab depletes the CD20+ B cells that are the EBV reservoir, and monomorphic PTLD resembling diffuse large B-cell lymphoma is treated with rituximab combined with chemotherapy (R-CHOP), following systemic lymphoma principles while balancing the immunosuppressive burden.
Option B: Option B is incorrect: ganciclovir remains ineffective for latency-driven PTLD regardless of histology.
Option C: Option C is incorrect: letermovir is CMV-specific and inactive against EBV.
Option D: Option D is incorrect: antiviral combinations do not treat established PTLD.
Option E: Option E is incorrect: monomorphic PTLD is aggressive and does not regress spontaneously; it requires active treatment. The progression from reduction of immunosuppression to rituximab to R-CHOP reflects the standard PTLD hierarchy.
13. [CASE 4 — QUESTION 1]
A 5-year-old boy receives a T-cell-depleted, mismatched unrelated-donor allogeneic HSCT. On surveillance peripheral blood PCR his adenovirus viral load is rising, and he develops hemorrhagic cystitis and transaminitis, signaling disseminating adenovirus disease. Which pharmacological agent is the principal treatment for adenovirus disease in this setting?
A) Ganciclovir, the agent of choice for adenovirus
B) Letermovir, which covers adenovirus through terminase inhibition
C) Cidofovir, an acyclic nucleoside phosphonate active against adenovirus that is the principal pharmacological agent for adenovirus disease in transplant recipients, despite the absence of high-quality randomized evidence
D) Oseltamivir, repurposed for adenovirus
E) Acyclovir at high dose, since adenovirus responds like HSV
ANSWER: C
Rationale:
Cidofovir is the principal agent for transplant-associated adenovirus disease. Option C is correct: cidofovir is an acyclic nucleoside phosphonate that, after host-cell phosphorylation, inhibits the adenovirus DNA polymerase; it is the principal pharmacological option for disseminated adenovirus in transplant recipients, though its use rests on observational data and mechanistic rationale rather than randomized trials.
Option A: Option A is incorrect: ganciclovir is not the agent of choice for adenovirus.
Option B: Option B is incorrect: letermovir is CMV-specific and inactive against adenovirus.
Option D: Option D is incorrect: oseltamivir is a neuraminidase inhibitor for influenza, not adenovirus.
Option E: Option E is incorrect: adenovirus does not respond to acyclovir as HSV does. Disseminated adenovirus in a T-cell-depleted recipient carries mortality exceeding 50%, underscoring the urgency of treatment alongside immune-restoration strategies.
14. [CASE 4 — QUESTION 2]
Continuing with the same patient. Cidofovir is selected. Which supportive protocol must accompany each infusion, and on what mechanism is it based?
A) Forced loop diuresis with potassium supplementation, to flush the drug through the tubule
B) Allopurinol pretreatment, to reduce a uric acid burden
C) N-acetylcysteine before and after the dose, to scavenge reactive oxygen species
D) Empiric calcineurin inhibitor dose reduction on infusion days, with no other measures
E) Oral probenecid before and after the infusion plus intravenous saline hydration, because cidofovir is taken into proximal tubular cells via the organic anion transporter OAT1; probenecid blocks that uptake and saline limits exposure, with the drug contraindicated below a defined creatinine-clearance threshold
ANSWER: E
Rationale:
Cidofovir's tubular uptake mechanism dictates a specific nephroprotective protocol. Option E is correct: cidofovir enters proximal tubular cells through OAT1, where accumulation causes nephrotoxicity; probenecid competitively blocks OAT1 uptake and saline hydration limits exposure, so each infusion is given with oral probenecid (before and after) and IV normal saline, with renal function and proteinuria checked before each dose and the drug contraindicated below the defined creatinine-clearance threshold.
Option A: Option A is incorrect: loop diuresis is not the protective strategy and could worsen volume status.
Option B: Option B is incorrect: allopurinol targets urate, irrelevant to cidofovir tubular uptake.
Option C: Option C is incorrect: N-acetylcysteine is not the established protocol.
Option D: Option D is incorrect: while calcineurin inhibitor levels are monitored because cidofovir-induced renal impairment reduces their clearance, prophylactic dose reduction is not the nephroprotective infusion protocol. This OAT1 mechanism is precisely what brincidofovir was designed to bypass.
15. [CASE 4 — QUESTION 3]
Continuing with the same patient. He develops rising creatinine on cidofovir, and the team considers brincidofovir. Which statement about brincidofovir is correct?
A) Brincidofovir is a wholly new pharmacophore that does not yield cidofovir or any cidofovir metabolite
B) Brincidofovir is a lipid conjugate of cidofovir that enters cells by lipid endocytosis rather than OAT1-mediated tubular uptake, sparing the proximal tubule while phospholipases release active cidofovir diphosphate intracellularly; however, a phase 3 trial in adenovirus-infected HSCT recipients did not show a survival benefit
C) Brincidofovir is more nephrotoxic than cidofovir and requires intensified probenecid
D) Brincidofovir requires viral kinase activation, which narrows its spectrum
E) Brincidofovir acts on the CMV terminase, unlike cidofovir
ANSWER: B
Rationale:
Brincidofovir's design preserves the cidofovir mechanism while avoiding the OAT1-driven toxicity, but its clinical adenovirus data are disappointing. Option B is correct: brincidofovir is a lipid (hexadecyloxypropyl) conjugate that enters cells via lipid endocytosis, bypassing OAT1 and sparing the proximal tubule, with intracellular phospholipases releasing active cidofovir diphosphate; nonetheless, a phase 3 trial in adenovirus-infected HSCT recipients did not demonstrate a survival benefit, attributed in part to the drug's own immunosuppressive effects at the doses studied.
Option A: Option A is incorrect: brincidofovir delivers the active cidofovir species intracellularly.
Option C: Option C is incorrect: its design reduces, not increases, nephrotoxicity.
Option D: Option D is incorrect: like cidofovir, it is activated by host (not viral) kinases, preserving broad dsDNA-virus coverage.
Option E: Option E is incorrect: brincidofovir works through the cidofovir/polymerase pathway, not the terminase. Brincidofovir is FDA-approved for smallpox (orthopoxvirus), with adenovirus use investigational.
16. [CASE 4 — QUESTION 4]
Continuing with the same patient. His adenovirus disease is refractory to cidofovir, and the underlying problem is profound deficiency of adenovirus-specific T-cell immunity. Which emerging strategy directly addresses this deficit?
A) Switching to high-dose acyclovir for broader coverage
B) Adding letermovir for synergistic terminase inhibition
C) Beginning systemic corticosteroids to control viral replication
D) Adoptive transfer of adenovirus-specific cytotoxic T lymphocytes expanded ex vivo from donor or third-party virus-specific T-cell lines, which reconstitutes the missing antiviral cellular immunity
E) Initiating oseltamivir for its activity against double-stranded DNA viruses
ANSWER: D
Rationale:
Refractory adenovirus in a T-cell-depleted host calls for restoring the missing cellular immunity. Option D is correct: adoptive transfer of adenovirus-specific cytotoxic T lymphocytes, expanded ex vivo from donor or third-party virus-specific T-cell lines, directly reconstitutes the deficient antiviral cellular immunity and is an emerging strategy with promising early results in cidofovir-refractory disease.
Option A: Option A is incorrect: acyclovir is not active against adenovirus.
Option B: Option B is incorrect: letermovir is CMV-specific and inactive against adenovirus.
Option C: Option C is incorrect: corticosteroids do not control viral replication and would deepen immunosuppression.
Option E: Option E is incorrect: oseltamivir is an influenza neuraminidase inhibitor with no activity against dsDNA viruses. Reconstituting virus-specific T-cell immunity reflects the recurring principle that, when pharmacological options are limited, restoring immune control is decisive.
17. [CASE 5 — QUESTION 1]
A 60-year-old woman with a kidney transplant at month 5 has a plasma BK polyomavirus load rising above 10,000 copies/mL, with serum creatinine increasing from 1.3 to 1.9 mg/dL. Allograft biopsy confirms BK polyomavirus nephropathy (BKPyVAN). She is on tacrolimus and mycophenolate. What is the cornerstone of management?
A) Reduce immunosuppression — lower the calcineurin inhibitor target and reduce or stop the antimetabolite — to restore BK-specific cytotoxic T-cell control, while monitoring graft function for rejection
B) Begin IV ganciclovir, which is virus-specific for BK polyomavirus
C) Start letermovir, repurposing its terminase activity against BK
D) Intensify immunosuppression to protect the graft from concurrent rejection
E) Proceed to immediate allograft nephrectomy
ANSWER: A
Rationale:
BK nephropathy is managed primarily by restoring immune control because effective antivirals are lacking. Option A is correct: the cornerstone is reduction of immunosuppression (lowering the calcineurin inhibitor target and reducing or stopping the antimetabolite) to allow BK-specific cytotoxic T-cell reconstitution, guided by serial plasma BK PCR, while monitoring graft function because the same reduction raises rejection risk.
Option B: Option B is incorrect: ganciclovir is not active against BK polyomavirus.
Option C: Option C is incorrect: letermovir is CMV-specific (the CMV terminase) and has no BK activity.
Option D: Option D is incorrect: intensifying immunosuppression worsens BK replication.
Option E: Option E is incorrect: nephrectomy is not first-line; the aim is to salvage the graft by restoring immune control. The central tension is balancing viral clearance against rejection risk.
18. [CASE 5 — QUESTION 2]
Continuing with the same patient. The family asks why she is not simply given an antiviral drug to clear the BK virus while keeping her immunosuppression unchanged. Which explanation is most accurate?
A) An effective BK antiviral exists but is being withheld for cost reasons
B) BK virus is harmless, so neither antivirals nor immunosuppression changes are warranted
C) No antiviral is approved or reliably effective against BK polyomavirus, so control depends on reducing immunosuppression to restore BK-specific T-cell immunity; the unavoidable tension is that this same reduction increases the risk of allograft rejection, requiring careful titration
D) Antivirals would work but cannot be combined with tacrolimus for chemical reasons
E) Increasing immunosuppression while giving an antiviral is the standard cure
ANSWER: C
Rationale:
This addresses both the lack of effective antivirals and the rejection-versus-virus balance unique to kidney transplantation. Option C is correct: there is no FDA-approved or reliably effective BK antiviral, so management depends on reducing immunosuppression to restore BK-specific cytotoxic T-cell control, with the central tension that the same reduction raises the risk of allograft rejection and must be titrated against graft function.
Option A: Option A is incorrect: no effective approved BK antiviral exists to withhold.
Option B: Option B is incorrect: BK nephropathy threatens the allograft and is not harmless.
Option D: Option D is incorrect: the absence of effective antivirals, not a chemical incompatibility, is the issue.
Option E: Option E is incorrect: increasing immunosuppression worsens BK replication. Low-dose cidofovir or leflunomide are reserved for refractory cases on limited evidence.
19. [CASE 5 — QUESTION 3]
Continuing with the same patient. Despite reduction of immunosuppression, her BK viral load and creatinine continue to rise. Which second-line pharmacological options may be considered, with appropriate caveats?
A) High-dose IV ganciclovir, now indicated because the disease is refractory
B) Letermovir, which becomes active against BK once immunosuppression is reduced
C) Acyclovir, which is activated by BK virus thymidine kinase
D) Valganciclovir prophylaxis, to prevent further BK replication
E) Low-dose cidofovir (often given without probenecid in this setting) or leflunomide, an immunomodulatory drug that also inhibits BK replication, recognizing that evidence for both is limited and observational
ANSWER: E
Rationale:
When immunosuppression reduction is insufficient, only weakly supported pharmacological options remain. Option E is correct: in refractory BK nephropathy, low-dose cidofovir (often without probenecid at these low doses) or leflunomide (which inhibits BK replication through pyrimidine synthesis inhibition while providing immunomodulation) may be considered, with the explicit caveat that evidence for both is limited and observational.
Option A: Option A is incorrect: ganciclovir is not active against BK polyomavirus regardless of disease severity.
Option B: Option B is incorrect: letermovir is CMV-specific and does not gain BK activity with immunosuppression changes.
Option C: Option C is incorrect: BK virus does not express a thymidine kinase that activates acyclovir.
Option D: Option D is incorrect: valganciclovir is inactive against BK and would only add toxicity. The weakness of these options underscores why immune restoration remains the primary lever in BK nephropathy.
20. [CASE 5 — QUESTION 4]
Continuing with the same patient. A trainee asks how BK polyomavirus management compares with CMV management in transplantation. Which statement correctly contrasts the two?
A) Both BK virus and CMV are managed primarily with reduction of immunosuppression, with no effective antivirals for either
B) Both BK virus and CMV have multiple effective approved antivirals, differing only in dosing
C) BK virus has effective antivirals while CMV does not, so the management priorities are reversed
D) CMV has multiple effective antivirals (ganciclovir/valganciclovir, foscarnet, cidofovir, and letermovir for prophylaxis), whereas BK virus has no approved or reliably effective antiviral, so BK management centers on reducing immunosuppression to restore T-cell control
E) Neither virus reactivates under immunosuppression, so neither requires monitoring
ANSWER: D
Rationale:
The defining contrast is the availability of effective antivirals. Option D is correct: CMV has multiple effective antivirals (ganciclovir/valganciclovir, foscarnet, cidofovir, and letermovir for prophylaxis), while BK virus has no approved or reliably effective antiviral, so BK management centers on reducing immunosuppression to restore BK-specific T-cell control.
Option A: Option A is incorrect: CMV very much has effective antivirals, so the claim of none for either is false.
Option B: Option B is incorrect: BK virus lacks effective approved antivirals.
Option C: Option C is incorrect: this reverses the truth — CMV, not BK, has effective antivirals.
Option E: Option E is incorrect: both viruses reactivate under immunosuppression and require surveillance. This contrast explains why immunosuppression reduction is the cornerstone for BK but one of several tools for CMV.
21. [CASE 6 — QUESTION 1]
A 46-year-old woman with multiple sclerosis, JC virus antibody-positive (index >1.5) and on natalizumab for 30 months, develops subacute right hemiparesis and personality change. MRI shows multifocal T2-hyperintense white-matter lesions without mass effect, and CSF JC virus PCR is positive, confirming progressive multifocal leukoencephalopathy (PML). Which initial management is correct?
A) Continue natalizumab to limit the CNS inflammation contributing to her deficits
B) Discontinue natalizumab immediately and consider plasma exchange to accelerate its clearance, since recovery depends on restoring JC virus-specific T-cell surveillance and no antiviral is effective against JC virus
C) Start high-dose cidofovir, which reliably clears JC virus
D) Begin IV ganciclovir, since JC virus is a polyomavirus like BK
E) Deepen immunosuppression to slow JC virus replication
ANSWER: B
Rationale:
This is high-risk natalizumab-associated PML (antibody-positive, high index, duration beyond 24 months). Option B is correct: management requires immediate discontinuation of natalizumab, with plasma exchange to hasten clearance, because recovery depends on restoring JC virus-specific cytotoxic T-cell surveillance and no antiviral is effective; the team must then anticipate immune reconstitution inflammatory syndrome.
Option A: Option A is incorrect: continuing natalizumab perpetuates the blockade of lymphocyte CNS entry that allowed PML.
Option C: Option C is incorrect: cidofovir has failed to show benefit against JC virus.
Option D: Option D is incorrect: ganciclovir is not active against JC virus despite the polyomavirus classification.
Option E: Option E is incorrect: deepening immunosuppression worsens PML by further impairing the needed T-cell response. Her risk profile reflects the validated stratification by antibody index, treatment duration, and prior immunosuppressant use.
22. [CASE 6 — QUESTION 2]
Continuing with the same patient. Her family asks why she developed PML even though she was not immunosuppressed in the usual transplant sense. Which explanation correctly links natalizumab's mechanism to her PML?
A) Natalizumab blocks alpha-4 integrin (very late antigen-4, VLA-4), preventing lymphocytes — including JC virus-specific cytotoxic T cells — from trafficking from blood into the central nervous system, so JC virus escapes CNS immune surveillance and causes PML; this is also why no antiviral substitutes for restoring that surveillance
B) Natalizumab depletes circulating CD20+ B cells, the reservoir of JC virus
C) Natalizumab directly reactivates latent JC virus within oligodendrocytes
D) Natalizumab suppresses the bone marrow, producing global lymphopenia
E) Natalizumab inhibits the JC virus DNA polymerase, paradoxically selecting resistant virus
ANSWER: A
Rationale:
The mechanism of natalizumab-associated PML is a localized failure of CNS immune surveillance. Option A is correct: natalizumab is an anti-alpha-4 integrin antibody that blocks VLA-4 binding to VCAM-1, preventing lymphocytes from trafficking into the CNS; this beneficially reduces multiple sclerosis inflammation but simultaneously removes JC virus-specific cytotoxic T-cell surveillance of the brain, allowing PML — which is why restoring surveillance, not antiviral therapy, is the basis of management.
Option B: Option B is incorrect: B-cell depletion describes rituximab, and PML control is a T-cell phenomenon.
Option C: Option C is incorrect: natalizumab does not directly reactivate the virus; it removes the immune patrol.
Option D: Option D is incorrect: it does not cause marrow suppression or global lymphopenia.
Option E: Option E is incorrect: natalizumab is not a polymerase inhibitor. Withdrawal restores — and can over-restore — CNS immunity, setting up the risk of immune reconstitution inflammatory syndrome.
23. [CASE 6 — QUESTION 3]
Continuing with the same patient. To illustrate a contrasting cause of post-transplant encephalitis, her neurologist describes a separate patient: a 38-year-old allogeneic HSCT recipient who, three weeks post-transplant during profound T-cell lymphopenia, develops acute confusion, dense anterograde amnesia, and a seizure, with bilateral medial temporal lobe T2/FLAIR signal on MRI and a positive CSF HHV-6 PCR. Which statement best directs management of that HSCT patient?
A) Plasma HHV-6 positivity alone would establish encephalitis, making CSF testing unnecessary
B) This is almost certainly inherited chromosomally integrated HHV-6, so antiviral therapy is contraindicated
C) Treat HHV-6B encephalitis with IV ganciclovir or foscarnet for at least three weeks or until clinical and virologic response, recognizing that CSF HHV-6 PCR — not plasma PCR — is required for diagnosis because asymptomatic plasma reactivation is common after HSCT
D) Empiric standard-dose acyclovir is adequate, since HHV-6 responds like HSV
E) Begin letermovir, since its terminase activity covers HHV-6 encephalitis
ANSWER: C
Rationale:
The week-3 timing during T-cell lymphopenia, the medial temporal MRI pattern, and CSF HHV-6 PCR positivity define post-transplant HHV-6B encephalitis. Option C is correct: HHV-6B encephalitis is treated with IV ganciclovir or foscarnet for at least three weeks or until response, and diagnosis rests on CSF HHV-6 PCR because plasma reactivation is common after HSCT (30-70%) without neurological disease.
Option A: Option A is incorrect: plasma positivity is nonspecific here, which is exactly why CSF testing is needed.
Option B: Option B is incorrect: the clinical syndrome with CSF positivity indicates active encephalitis requiring treatment, not an integrated carrier state (iciHHV-6 would be confirmed by hair follicle testing in an asymptomatic patient).
Option D: Option D is incorrect: HHV-6 is treated with ganciclovir or foscarnet, not standard-dose acyclovir.
Option E: Option E is incorrect: letermovir is CMV-specific and not used for HHV-6. The medial temporal pattern resembles HSV encephalitis but lacks the hemorrhagic component.
24. [CASE 6 — QUESTION 4]
Continuing with the same patient. After natalizumab withdrawal and plasma exchange, her lymphocyte trafficking into the central nervous system rapidly returns, and her PML lesions transiently worsen with new inflammation even as JC virus appears to be coming under immune control. Which principle explains this development?
A) This is antiviral drug resistance, since the lesions worsened despite therapy
B) This is primary treatment failure, indicated by the worsening lesions
C) This is direct plasma-exchange toxicity to the brain, unrelated to immune status
D) This is immune reconstitution inflammatory syndrome (IRIS): as suppressed CNS immune surveillance is rapidly restored, the returning immune response drives paradoxical inflammation against JC virus antigen in the PML lesions — the same restored immunity that controls the virus can transiently worsen disease, sometimes requiring corticosteroids
E) This is a new, unrelated CNS infection, since IRIS cannot affect existing lesions
ANSWER: D
Rationale:
This final question ties the module's recurring theme — immune restoration as a double-edged sword — to this patient. Option D is correct: IRIS is a paradoxical inflammatory worsening of an existing infection as suppressed immunity recovers; after natalizumab withdrawal (hastened by plasma exchange), the rapid return of lymphocyte CNS trafficking can inflame PML lesions even as JC virus comes under control, sometimes requiring corticosteroids to temper the inflammation without abrogating immune recovery.
Option A: Option A is incorrect: no effective antiviral is being used against JC virus, so resistance is not the mechanism.
Option B: Option B is incorrect: improving viral control argues against treatment failure.
Option C: Option C is incorrect: the phenomenon is immune-mediated, not direct plasma-exchange toxicity.
Option E: Option E is incorrect: IRIS characteristically flares existing lesions rather than representing a new infection. The same immune-reconstitution principle explains worsening of treated CMV retinitis on antiretroviral therapy and unmasking of EBV, adenovirus, or HHV-6 when transplant immunosuppression is reduced.
This Web-based pharmacology and disease-based integrated teaching site is based on reference materials that are believed reliable and consistent with standards accepted at the time of development.
Possibility of error and on-going research and development in medical sciences do not allow assurance that the information contained herein is in every respect accurate or complete.
Users should confirm the information contained herein with other sources.
This site should only be considered as a teaching aid for undergraduate and graduate biomedical education and is intended only as a teaching site.
Information contained here should not be used for patient management and should not be used as a substitute for consultation with practicing medical professionals.
Users of this website should check the product information sheet included in the package of any drug they plan to administer to be certain that the information contained in this site is accurate and that changes have not been made in the recommended dose or in the contraindications for administration.
Medical or other information thus obtained should not be used as a substitute for consultation with practicing medical or scientific or other professionals.